A Phase II Clinical Trial of Recombinant Interferon-γ on Myelodysplastic Syndromes

  • M. Ogawa
  • Y. Yoshida
  • Y. Moriyama
  • K. Ezaki
  • M. Shimoyama
  • H. Mizoguchi
  • I. Urushizaki
  • T. Miyazaki
  • Y. Yoshida
  • A. Togawa
  • K. Toyama
  • Y. Kuraishi
  • T. Nakamura
  • K. Tamura
  • H. Sato
Conference paper

Abstract

Myelodysplastic syndromes (MDS) have attracted considerable interest both in Japan and abroad since the concept was first proposed by the FAB group [1]. However, effective methods of treatment have still not been established, except for bone marrow transplantation [2, 3]. Although the etiology of MDS is unclear, it is assumed that an abnormality at the pluripotent hematopoietic stem cell level is involved, and an ideal method of treatment appears to be replacement of the hematopoietic system with hematopoietic stem cells of healthy donors, i.e., allogeneic bone marrow transplantation. However, bone marrow transplantation is indicated only for young patients with matched bone marrow donors [3, 4]. Since MDS are prevalent in middle-aged or older patients, these patients cannot be considered candidates for bone marrow transplantation.

Keywords

Fatigue Toxicity Europe Lymphoma Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199PubMedGoogle Scholar
  2. 2.
    Buzaid AC, Garewal HS, Greenberg BR (1986) Management of myelodysplastic syndromes. Am J Med 80: 1149–1157PubMedCrossRefGoogle Scholar
  3. 3.
    Tricot G, Boogaerts MA, Verwilghen RL (1986) Treatment of patients with myelodysplastic syndromes. A review. Scand J Haematol 36 [Suppl 451: 121–127Google Scholar
  4. 4.
    Appelbaum FR, Storb R, Ramberg RE, Shulman HM, Buckner CD, Clift RA, Deeg HJ, Fefer A, Sanders J, Self S, Singer J, Stewart P, Sullivan K, Witherspoon R, Thomas ED (1987) Treatment of preleukemic syndromes with marrow transplantation. Blood 69: 92–96PubMedGoogle Scholar
  5. 5.
    Yoshida Y, Oguma S, Yamagishi M, Uchino H, Maekawa T (1988) Prednisolone la-hydroxyvitamin D3 and androgens in the management of patients with refractory anemias. Myelodysplastic Syndromes Pathophysiology and treatment. In: Uchino H, Takaku F, Yoshida Y (eds) Elsevier, Amsterdam, pp 189–202Google Scholar
  6. 6.
    Spriggs DR, Stone RM, Kufe DW (1986) The treatment of myelodysplastic syndromes. Clin Haematol 15: 1081–1109PubMedGoogle Scholar
  7. 7.
    Yoshida Y, Sakota H, Ohmori S, Tohyama K, Ueda T, Ueda Y, Uchino H (1987) Marrow culture studies of myelodysplastic syndromes ( MDS ). Exp HematoI 15: 568Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. Ogawa
    • 1
  • Y. Yoshida
    • 2
  • Y. Moriyama
    • 3
  • K. Ezaki
    • 3
  • M. Shimoyama
    • 3
  • H. Mizoguchi
    • 3
  • I. Urushizaki
    • 3
  • T. Miyazaki
    • 3
  • Y. Yoshida
    • 3
  • A. Togawa
    • 3
  • K. Toyama
    • 3
  • Y. Kuraishi
    • 3
  • T. Nakamura
    • 3
  • K. Tamura
    • 3
  • H. Sato
    • 3
  1. 1.Japanese Foundation for Cancer ResearchToshima-ku, Tokyo 170Japan
  2. 2.Department of Internal Medicine IKyoto UniversitySakyo, Kyoto 606Japan
  3. 3.Japanese Interferone-γ Research Group, C/O Basic Research LaboratoriesToray Industries, Inc.Kamakura 248Japan

Personalised recommendations